ArticleDiscover oncology2026
Intravenous paclitaxel delivered by a vitamin E nanocarrier as a safe and economical alternative to albumin-bound nanoparticles.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPaclitaxel is a widely used chemotherapeutic agent for solid tumors; however, its clinical application is limited by extremely low aqueous solubility and the use of toxic excipients in conventional formulations. Albumin-bound paclitaxel nanoparticles improve solubility but remain costly and present challenges related to stability and manufacturing. This study aimed to develop a synthetic and economical TPGS-based solubilization system as an alternative to intravenous paclitaxel formulations with enhanced anticancer efficacy.
methodsA series of D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) micelles and TPGS–cosolvent systems were prepared and evaluated for solubilization efficiency, particle size, and homogeneity. The promising formulation (F3) was examined for in vitro cytotoxicity in MCF-7, MDA-MB-231, HeLa, and HCT116 cell lines. Mechanistic studies, including cell-cycle analysis, Annexin V/PI apoptosis staining, assessment of mitochondrial membrane potential (MMP), and DAPI nuclear imaging, were conducted to characterize the anticancer activity in MCF-7 cells.
resultsF3 markedly improved paclitaxel solubility and formed nanosized homogenous micellar dispersions suitable for intravenous delivery. Across all cell lines, F3 demonstrated significantly enhanced cytotoxicity, producing 4–7-fold lower IC₅₀ values compared with free paclitaxel and albumin-bound paclitaxel (Taxonab®). In MCF-7 cells, F3 induced prominent G₂/M arrest, the highest Sub-G1 apoptotic population, and pronounced mitochondrial depolarization, consistent with mitochondria-mediated apoptosis. DAPI staining confirmed nuclear fragmentation and reduced cell density.
conclusionThe TPGS-based paclitaxel formulation significantly enhances drug solubility, cellular uptake, and apoptotic activity, outperforming both free paclitaxel and albumin-bound nanoparticles. This synthetic, scalable, and cost-effective platform represents a promising alternative for intravenous paclitaxel delivery and warrants further preclinical evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.